Navigation Links
Genprex Announces New Patent Issuance in Japan
Date:10/18/2011

AUSTIN, Texas, Oct. 18, 2011 /PRNewswire/ -- A new patent covering tumor suppression technologies, including the company's lead product candidate Oncoprex™, was recently awarded to The University of Texas System by the Japan Patent Office. Patent number 4813746 pertains to the discovery that chromosome 3p21.3 genes act as cancer suppressors. The family of tumor suppressors include TUSC2, also known as FUS1, the anti-cancer agent in Oncoprex therapy which is undergoing clinical evaluation for lung cancer patients in the U.S.

"Japan represents an important clinical population," stated Chief Operating and Financial Officer Greg Heinlein. "We intend to include Japanese collaborators in our development and commercialization plans and have begun to establish key relations within the region, including appointments of leading oncology experts to our Medical and Scientific Advisory Board."

Genprex controls a portfolio of biomedical technologies including targeted molecular therapeutics for cancer and other diseases. The novel technologies, including those licensed exclusively from The University of Texas MD Anderson Cancer Center, are protected by 15 issued patents and 9 pending applications in major market areas. These broadly applicable technologies have been the subject of more than 20 peer-reviewed scientific publications in the fields of cancer, genomics and molecular biology.

About Oncoprex™Oncoprex is a nanomolecular therapy harnessing the TUSC2 tumor suppressor. TUSC2 defects are associated with most major cancers and >85% of lung cancers. Intravenous Oncoprex induces apoptosis or programmed cell death in cancer cells and controls cell signaling and inflammation to fight cancer along universal cancer pathways. In phase I clinical testing of Stage IV lung cancer patients, Oncoprex monotherapy was well tolerated and demonstrated clinically significant anti-cancer activity in primary lung tumors and metastatic tumors, including liver and pancreas. A phase II clinical trial evaluating Oncoprex in combination with Tarceva® (erlotinib) is planned for 2012. The trial will enroll lung cancer patients without the EGFR mutation and patients with EGFR mutations who have become unresponsive to erlotinib.

About GenprexGenprex, Inc. is a privately held, clinical-stage biopharmaceutical company developing nanomolecular therapies that control universal cancer pathways to unlock the unrealized potential of a variety of targeted cancer therapies. For more information about Genprex click here. Tarceva® is a registered trademark of the Roche Group, including Genentech and Chugai, and of Astellas Pharma.Contact:

Greg HeinleinPhone:

512-597-5900www.genprex.com
'/>"/>

SOURCE Genprex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. SomaLogic Announces Research Agreement with Leading Global Pharmaceutical Company to Accelerate Pharmaceutical Discovery and Development
2. Rock Creek Pharmaceuticals Announces Expanded International Shipping Options for Anatabloc™, Physician Conferences on Anatabine Research
3. Hologic Announces Jury Verdict in Patent Infringement Suit
4. Regeneron Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes due October 1, 2016
5. Aethlon Medical Announces Availability of its Exosome Detection Assay to the Research Community
6. Hospira Announces Certain Preliminary Third-Quarter 2011 Results
7. Ampio Pharmaceuticals Announces a Proof of Concept Trial of Danazol in the Treatment of Allergic Rhinitis Supports Mechanism of Action of Optina™
8. Bend Research Announces Schedule of Events at 2011 AAPS Annual Meeting and Exposition
9. Pacira Pharmaceuticals, Inc. Announces Key EXPAREL™ Data to be Presented at American College of Surgeons 97th Annual Clinical Congress
10. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
11. Express Scripts Announces Third Quarter 2011 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , Jan 18, 2017 Research and Markets ... by Product, by End User - Global Opportunity Analysis and Industry Forecast, ... ... 2015 and is expected to reach $5,491 million by 2022, growing at ... North America was the leading regional market in global ...
(Date:1/18/2017)... SAN JOSE, Calif. , Jan. 18, 2017  Adaptive ... machines, announced today a new partnership with Hyatt Place ... guests by providing ASTI LectroFan sleep therapy machines in ... "Obviously one of the most important parts of having ... Wicks , general manager of Hyatt Place Nashville/Downtown. "We,re ...
(Date:1/18/2017)... , Jan. 18, 2017   Regenicin, Inc. ... company specializing in the development and commercialization of regenerative ... and organs, recently reported the Company,s operating results for ... As the Company described in its recent ... year of substantial accomplishments. The Company,s contract laboratory completed ...
Breaking Medicine Technology:
(Date:1/19/2017)... Chicago, IL (PRWEB) , ... January 19, 2017 ... ... Bank, N.A., announced it recently provided a new $11,250,000 senior credit facility to ... the new MB credit facility were used to facilitate a recapitalization of MedPro ...
(Date:1/19/2017)... Huntington Beach, CA (PRWEB) , ... January 19, ... ... for Oral Health, is now offering treatments for patients with sleep apnea and ... far-reaching consequences for dental and physical health. Dr. Rassouli provides personalized care to ...
(Date:1/19/2017)... Francisco, CA (PRWEB) , ... January 19, 2017 , ... ... financial planning assistance to commercial and residential clients in the California Bay Area, is ... positive heart health in the region. , Heart disease is the primary killer of ...
(Date:1/19/2017)... ... 2017 , ... St. Catherine’s Village announced that a limited number of rooms ... facility on the grounds of the St. Catherine’s Village campus in Madison, Mississippi that ... nursing home in Mississippi for the second year in a row by readers of ...
(Date:1/19/2017)... ... January 18, 2017 , ... The CHP suggests that California drivers can ... by slowing down and increasing the space between themselves and other vehicles, according to ... accident attorney Raymond R. Hassanlou notes that, rain or shine, drivers should always incorporate ...
Breaking Medicine News(10 mins):